These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 11701453)

  • 1. Lp A-I and niacin: new views of an antiatherogenic duo.
    Saucan L; Brinton EA
    Arterioscler Thromb Vasc Biol; 2001 Nov; 21(11):1707-9. PubMed ID: 11701453
    [No Abstract]   [Full Text] [Related]  

  • 2. Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol.
    Sakai T; Kamanna VS; Kashyap ML
    Arterioscler Thromb Vasc Biol; 2001 Nov; 21(11):1783-9. PubMed ID: 11701466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Of mice and men: blowing away the cobwebs from the mechanism of action of niacin on HDL metabolism.
    Watts GF; Chan DC
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):1892-5. PubMed ID: 18946055
    [No Abstract]   [Full Text] [Related]  

  • 4. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.
    van der Hoorn JW; de Haan W; Berbée JF; Havekes LM; Jukema JW; Rensen PC; Princen HM
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2016-22. PubMed ID: 18669886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein-AI-containing particles and atherosclerosis.
    Fruchart JC; Castro G; Duriez P
    Isr J Med Sci; 1996 Jun; 32(6):498-502. PubMed ID: 8682658
    [No Abstract]   [Full Text] [Related]  

  • 6. Human apolipoprotein A-II enrichment displaces paraoxonase from HDL and impairs its antioxidant properties: a new mechanism linking HDL protein composition and antiatherogenic potential.
    Ribas V; Sánchez-Quesada JL; Antón R; Camacho M; Julve J; Escolà-Gil JC; Vila L; Ordóñez-Llanos J; Blanco-Vaca F
    Circ Res; 2004 Oct; 95(8):789-97. PubMed ID: 15388641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular regulation of HDL metabolism and function: implications for novel therapies.
    Rader DJ
    J Clin Invest; 2006 Dec; 116(12):3090-100. PubMed ID: 17143322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ApoA-II versus ApoA-I: two for one is not always a good deal.
    Castellani LW; Lusis AJ
    Arterioscler Thromb Vasc Biol; 2001 Dec; 21(12):1870-2. PubMed ID: 11742857
    [No Abstract]   [Full Text] [Related]  

  • 9. Remodelling of high density lipoproteins by plasma factors.
    Rye KA; Clay MA; Barter PJ
    Atherosclerosis; 1999 Aug; 145(2):227-38. PubMed ID: 10488948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging therapies targeting high-density lipoprotein metabolism and reverse cholesterol transport.
    Duffy D; Rader DJ
    Circulation; 2006 Feb; 113(8):1140-50. PubMed ID: 16505192
    [No Abstract]   [Full Text] [Related]  

  • 11. Antioxidant supplements and simvastatin-niacin therapy.
    Netke S; Ivanov V; Roomi W; Niedzwiecki A; Rath M
    Arterioscler Thromb Vasc Biol; 2001 Dec; 21(12):2099-100. PubMed ID: 11742891
    [No Abstract]   [Full Text] [Related]  

  • 12. Pyrazole acids as niacin receptor agonists for the treatment of dyslipidemia.
    Schmidt D; Smenton A; Raghavan S; Carballo-Jane E; Lubell S; Ciecko T; Holt TG; Wolff M; Taggart A; Wilsie L; Krsmanovic M; Ren N; Blom D; Cheng K; McCann PE; Gerard Waters M; Tata J; Colletti S
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4768-72. PubMed ID: 19592242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ask the doctor. I tried taking niacin to increase my HDL but didn't like the flushing it caused. A friend told me about no-flush niacin, which works like a charm. Why not tell your readers about it?
    Lee T
    Harv Heart Lett; 2010 Mar; 20(7):8. PubMed ID: 20586132
    [No Abstract]   [Full Text] [Related]  

  • 14. Rosuvastatin selectively stimulates apolipoprotein A-I but not apolipoprotein A-II synthesis in Hep G2 cells.
    Qin S; Koga T; Ganji SH; Kamanna VS; Kashyap ML
    Metabolism; 2008 Jul; 57(7):973-9. PubMed ID: 18555840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of dietary phytosterols plus niacin or fenofibrate: effects on lipid profile and atherosclerosis in apo E-KO mice.
    Yeganeh B; Moshtaghi-Kashanian GR; Declercq V; Moghadasian MH
    J Nutr Biochem; 2005 Apr; 16(4):222-8. PubMed ID: 15808326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NDRG1 interacts with APO A-I and A-II and is a functional candidate for the HDL-C QTL on 8q24.
    Hunter M; Angelicheva D; Tournev I; Ingley E; Chan DC; Watts GF; Kremensky I; Kalaydjieva L
    Biochem Biophys Res Commun; 2005 Jul; 332(4):982-92. PubMed ID: 15922294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-density lipoprotein metabolism: potential therapeutic targets.
    Davidson MH; Toth PP
    Am J Cardiol; 2007 Dec; 100(11 A):n32-40. PubMed ID: 18047851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bibliography. Current world literature. HDL cholesterol.
    Curr Opin Cardiol; 2008 Jul; 23(4):426-9. PubMed ID: 18536113
    [No Abstract]   [Full Text] [Related]  

  • 19. Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-alpha.
    Qin S; Liu T; Kamanna VS; Kashyap ML
    Arterioscler Thromb Vasc Biol; 2007 Nov; 27(11):2428-34. PubMed ID: 17872455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different VLDL apo B, and HDL apo AI and apo AII metabolism in two heterozygous carriers of unrelated mutations in the lipoprotein lipase gene.
    Pérez-Méndez O; Duhal N; Lacroix B; Bonte JP; Fruchart JC; Luc G
    Clin Chim Acta; 2006 Jun; 368(1-2):149-54. PubMed ID: 16487502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.